


CLAIMS

1. Use of an α -aminoamide of formula (I):



wherein:

A is a $-(CH_2)_m-$ or $-(CH_2)_n-X-$; wherein m is 1 or 2; n is zero, 1 or 2; and X is $-O-$, $-S-$ or $-NH-$:

R is a furyl, thienyl, or pyridyl ring or a phenyl ring, unsubstituted or substituted by one or two substituents independently selected from halogen, hydroxy, C₁-C₄ alkyl, C₁-C₃ alkoxy and trifluoromethyl;

R₁ is hydrogen or C₁-C₃ alkyl;

R₂ is hydrogen or C₁-C₂ alkyl, unsubstituted or substituted by hydroxy or phenyl; phenyl, unsubstituted or substituted by one or two substituents independently selected from C₁-C₃ alkyl, halogen, hydroxy, C₁-C₂ alkoxy or trifluoromethyl;

R₃ is hydrogen or C₁-C₃ alkyl;

if the case, either as a single isomer, or as a mixture thereof, or a pharmaceutically acceptable derivative thereof.

in the manufacture of a medicament for the treatment of head pain conditions involving a cerebral vasodilatation mechanism.

2. Use of an α -aminoamide according to claim 1, wherein in formula (I):

A is a group selected from $-\text{CH}_2-\text{CH}_2-$, $-\text{CH}_2-\text{O}-$, $-\text{CH}_2-\text{S}-$, $-\text{CH}_2-\text{CH}_2-\text{O}-$:

R is a phenyl ring, unsubstituted or substituted by one or two substituents independently selected from halogen, C₁-C₃ alkyl or a methoxy group; or a thienvyl ring.

R_1 is hydrogen or C_1-C_2 alkyl:

R₂ is hydrogen or methyl, unsubstituted or substituted by hydroxy, or phenyl unsubstituted or substituted by C₁-C₂ alkyl, halogen, hydroxy, methoxy or trifluoromethyl; and

R_3 is hydrogen or C_1-C_2 alkyl.

BEST AVAILABLE COPY

3. Use of an α -aminoamide according to claim 1 or 2, wherein in formula (I):

A is $-\text{CH}_2-\text{O}-$, $-\text{CH}_2-\text{S}-$ or $-\text{CH}_2-\text{CH}_2-$;

R is a phenyl ring, unsubstituted or substituted by one or two halogen atoms;

R_1 is hydrogen;

R_2 is hydrogen or methyl, unsubstituted or substituted by hydroxy or phenyl ring, unsubstituted or substituted by a halogen atom; and

R_3 is hydrogen or methyl.

4. Use of an α -aminoamide according to claim 1, wherein the α -aminoamide is selected from:

2-(4-benzyloxybenzylamino)propanamide;

2-[4-(2-fluorobenzyloxy)benzylamino]propanamide;

2-[4-(2-chlorobenzyloxy)benzylamino]propanamide;

2-[4-(3-fluorobenzyloxy)benzylamino]propanamide;

2-[4-(3-chlorobenzyloxy)benzylamino]propanamide;

2-[4-(4-fluorobenzyloxy)benzylamino]propanamide;

2-[4-(2-fluorobenzyloxy)benzylamino]-N-methyl-propanamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-N-methyl-propanamide;

2-[4-(2-fluorobenzyloxy)benzylamino]-3-hydroxy-propanamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-3-hydroxy-propanamide;

2-(4-benzyloxybenzylamino)-3-hydroxy-N-methylpropanamide;

2-[4-(2-fluorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;

2-[4-(3-chlorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;

2-(4-(2-thienylmethylenoxy)benzylamino)-propanamide;

2-[4-(2-(3-fluorophenyl)ethyl)benzylamino]-propanamide;

2-[4-benzylthiobenzylamino]-propanamide;

2-[4-benzyloxybenzylamino]-3-phenyl-N-methylpropanamide;

BEST AVAILABLE COPY

2-[4-benzyloxybenzylamino] N-methylbutanamide;
2-[4-benzyloxybenzylamino]-2-phenyl-acetamide;
2-[4-(2-fluorobenzyloxy)benzylamino]-2-phenyl-acetamide;
2-[4-(3-fluorobenzyloxy)benzylamino]-2-phenyl-acetamide;
2-[4-(3-chlorobenzyloxy)benzylamino]-2-phenyl-acetamide;
2-[4-(3-fluorobenzyloxy)benzylamino]-2-(2-fluorophenyl)-acetamide;

2-[4-(3-fluorobenzyloxy)benzylamino]-2-(3-fluorophenyl)-acetamide;

2-[4-(3-chlorobenzyloxy)benzylamino]-2-(3-fluorophenyl)-acetamide;

if the case, either as a single isomer or as a mixture thereof, or a pharmaceutically acceptable derivative thereof.

5. Use of an α -aminoamide according to any of the previous claims, wherein the α -aminoamide is selected from: (S)-(+)-2-[4-(3-fluorobenzyloxy)benzylamino]-propanamide, (S)-(+)-2-[4-(2-fluorobenzyloxy)benzylamino]-propanamide and (S)-(+)-2-[4-(3-chlorobenzyloxy)benzylamino]-propanamide.

6. Use according to any of the previous claims, wherein head pain conditions are both primary and secondary headache disorders.

7. Use according to any of the previous claims, wherein head pain conditions include migraine, headache, hemicrania.

8. Use according to any of the previous claims, wherein migraine is acute, transformed or vascular migraine; headache is acute, cluster, evolutive or tension type headache; hemicrania is chronic paroxysmal hemicrania.

9. A method for the treatment of head pain conditions involving a cerebral vasodilatation mechanism in a mammal in need thereof comprising administering to the mammal a therapeutically effective dose of at least one α -aminoamide of formula (I) as defined in any of claims 1 to 5.

10. A method according to the previous claim, wherein the mammal is administered a dose of the α -aminoamide of formula (I)

BEST AVAILABLE COPY

SEARCHED SHEET

as defined in any of claims 1 to 5 which ranges from about 0.05 to 20 mg/kg body weight per day.

11. A method according to claim 9 or 10, wherein the mammal is administered a dose of the α -aminoamide of formula (I) as defined in any of claims 1 to 5 which ranges from about 0.5 to 10 mg/kg day.

12. A method according to any of claims from 9 to 11, wherein the mammal is administered a dose of the α -aminoamide of formula (I) as defined in any of claims 1 to 5 which ranges from about 0.5 to 5 mg/kg day.

13. A method according to any of claims from 9 to 12, wherein the head pain conditions are as defined in any of claims 6 to 8.

BEST AVAILABLE COPY